Ashley N. Payne

Ashley N. Payne

Auto-generated profile, based on publicly available information

Ashley N. Payne

Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
JSJames D. Slover
James D. Slover
KMKathleen A. Mullaly
Kathleen A. Mullaly
APAshley Payne
Ashley Payne
RIRichard Iorio
Richard Iorio
JBJoseph Bosco
Joseph Bosco

28 October 2025 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
RTRoman Thaler
Roman Thaler
APAshley N. Payne
Ashley N. Payne
DBDaniel J. Berry
Daniel J. Berry
MAMatthew P. Abdel
Matthew P. Abdel
Knee arthrofibrosis (AF) is a debilitating complication after total knee arthroplasty. AF is characterized by formation of fibrotic adhesions, loss of joint mobility, and pain. With osteoarthritis prevalence and associated total knee arthroplasties projected to rise sharply, AF is becoming increasingly prevalent, yet its pathogenesis remains poorly understood and no effective treatments exist. Like other fibrotic diseases, knee AF is a multifactorial disease that exhibits TGFβ1-driven myofibroblast transformation and excessive collagen deposition. However, knee AF also displays unique features, including rapid disease development and the establishment of a highly fibrotic mass rather than fibrotic tissue infiltration. Our integrative research approach uses human patient fibroblasts, multiomics profiling, and in vivo animal models to dissect disease mechanisms and identify therapeutic targets. Our work suggests altered adipogenic cell differentiation in the knee and epigenetic pathways controlling myofibroblastogenesis to be involved in AF development. Anti-inflammatory interventions with ketotifen and celecoxib reduce knee AF in vivo, indicating a contributory role of inflammation as well. Together, our novel findings elucidate causal and mechanistic drivers of AF and define this disease as an adipose-depleted fibrotic disorder driven by aberrant differentiation and epigenetic regulation, suggesting new therapeutic avenues for intervention.

1 November 2025 in Tissue Engineering Part C: Methods
Verified
Journal Article
Closed access
KAKareme D. Alder
Kareme D. Alder
MCMason F. Carstens
Mason F. Carstens
CBCole E. Bothun
Cole E. Bothun
ODOliver B. Dilger
Oliver B. Dilger
APAshley N. Payne
Ashley N. Payne
MAMatthew P. Abdel
Matthew P. Abdel
Arthrofibrosis is a common complication following total knee arthroplasty and is the result of a dysregulated immuno-inflammatory cascade, which culminates in excessive scar deposition by myofibroblasts within the knee joint. Pharmacotherapies for arthrofibrosis are limited, with treatment reliant on manipulation under anesthesia or lysis of adhesions with or without component revision. Bupivacaine (a local anesthetic) and meloxicam (a nonsteroidal anti-inflammatory drug) combination therapy may exert antifibrotic properties by limiting inflammatory cell recruitment and the subsequent release of profibrotic cytokines. The purpose of this study was to evaluate the effects of this combination therapy in a rabbit model of arthrofibrosis by evaluating live and postsacrifice knee biomechanics and gene expression of posterior knee capsule tissue. Forty New Zealand white rabbits were equally divided into two experimental groups and prospectively studied to assess knee passive extension angles (PEA), terminal posterior capsular stiffness, and the inflammatory milieu of the posterior knee joint capsule. Experimental limbs with and without combination therapy showed similar live PEAs and terminal posterior capsular stiffness, with no significant differences between the groups. Gene expression analysis, however, revealed significant reduction in inflammatory genes but not profibrotic genes. In summary, bupivacaine and meloxicam combination therapy did not exert antifibrotic effects in a rabbit model of arthrofibrosis but significantly reduced the expression of inflammatory markers in the local environment of the posterior capsule.